deoxyclavulanic acid | 69779-62-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: deoxyclavulanic acid
• 英文别名: (2R,3Z,5R)-3-ethylidene-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 69779-62-0
• 化学式: C₈H₉NO₄
• 分子量: 183.164
• InChiKey: NANZRLBCRZGDHH-MJFKMAHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙烷,三氯氟- 、 deoxyclavulanic acid 在 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以50%的产率得到N-p-tolyldeoxyclavulanamide
  参考文献：
  名称：

  Brown, Allan G.; Corbett, David F.; Goodacre, Jennifer, Journal of the Chemical Society. Perkin transactions I, 1984, # 4, p. 635 - 650

  摘要：

  DOI：
• 作为产物：
  描述：

  Benzyl Clavulanate 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、98.06 kPa 条件下， 反应 4.5h， 生成 deoxyclavulanic acid
  参考文献：
  名称：

  Brown, Allan G.; Corbett, David F.; Goodacre, Jennifer, Journal of the Chemical Society. Perkin transactions I, 1984, # 4, p. 635 - 650

  摘要：

  DOI：

文献信息

• Neurotherapeutic Compositions and Method
  申请人：Koppel Gary A.

  公开号：US20080200447A1

  公开（公告）日：2008-08-21

  Administration of β-Lactam compounds, including β-lactam antibiotics and β-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidence inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
• NEUROTHERAPEUTIC COMPOSITION AND METHOD THEREFOR
  申请人：Koppel Gary A.

  公开号：US20100249090A1

  公开（公告）日：2010-09-30

  Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are β-lactam compounds, particularly penam and cephem β-lactam antibiotics and non-antibiotic derivatives thereof.
• COMPOSITIONS INCLUDING CLAVULANIC ACID AND RELATED METHODS OF USE
  申请人：Watson Alan

  公开号：US20110190252A1

  公开（公告）日：2011-08-04

  Methods of treating a disorder in a subject comprising administering to a subject an elastase inhibitor such as clavulanic acid, sulbactam, or tazobactam are described.
• COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES
  申请人：SPERO TRINEM, INC.

  公开号：US20170128471A1

  公开（公告）日：2017-05-11

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.
• US7842683B2
  申请人：——

  公开号：US7842683B2

  公开（公告）日：2010-11-30